Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Infants may be eligible for this study if they:~* Were full term infants (at least 32 weeks gestation).~* Are 1 month of age or younger (preferably less than 2 weeks).~* Weighed at least 1,200 grams (2.5 lbs) at birth.~* Have confirmed cytomegalovirus.~* Have evidence of CMV infection of the CNS with or without evidence of other organ involvement.~Exclusion Criteria:~Infants will not be eligible for this study if they:~* Have concurrent bacterial infection.~* Have HIV infection.~* Have mild symptoms or no symptoms of CMV infection at birth.~* Have an abnormal brain development (hydranencephaly) or any devastating brain involvement.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).